JERUSALEM, Dec. 4, 2014 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) announced that it received a CE Marketing Approval, enabling it to immediately market and sell Brainsway Deep TMS (Deep Transcranial Magnetic Stimulation) in Europe, for treatment of Multiple Sclerosis (MS), Stroke and Obsessive Compulsive Disorder (OCD).
These new indications join Brainsway's numerous CE approvals for treating brain disorders, including autism, Alzheimer's disease, bipolar disorder, chronic pain, major depressive disorder, Parkinson's disease, post-traumatic stress disorder, schizophrenia (negative symptoms(, and smoking cessation.
"We are glad to be able to bring light into the lives of more brain disorder patients," said Shmulik Adler, VP Business Development and Reimbursement, Brainsway. "The new CE approvals allow Brainsway Deep TMS to provide an effective, safe and well-tolerated solution for the severe conditions of Multiple Sclerosis (MS), Stroke and Obsessive Compulsive Disorder (OCD). Brainsway intends to promote approval for these indications in additional markets in which we are active."
Brainsway Ltd. is dedicated to the development and marketing of Deep TMS (Deep Transcranial Magnetic Stimulation) systems, for treatment of brain disorders. The unique technology of Brainsway is based on patents filed by the National Institute of Health (NIH), and by the company. Brainsway has an exclusive license from the NIH for the patent and technology. Brainsway's technology was cleared by the FDA for treatment of depression patients who did not respond to any number of medication treatments in the current depressive episode. Brainsway's Deep TMS was enthusiastically received by the international academic community, with 60 clinical trials held in major institutions worldwide.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
CONTACT: For further information, please contact: Shmulik Adler VP Business Development and Reimbursement Brainsway Ltd. Tel: +972 2 5824030 Email: firstname.lastname@example.orgSource:Brainsway Ltd.